Last reviewed · How we verify
Ryzodeg®
At a glance
| Generic name | Ryzodeg® |
|---|---|
| Sponsor | Novo Nordisk A/S |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Safety and Efficacy of Insulin Degludec/Insulin Aspart in Patients With T2DM (NA)
- A Research Study, Looking at How Ryzodeg® (Insulin Degludec/Insulin Aspart) Works in People With Type 2 Diabetes in Local Clinical Practice
- China Research of IDEgAsp Treatment in Real-world Clinical practicE (CREATE)
- Investigating the Effect of Ryzodeg® in Adult Patients With Type 2 Diabetes in Lebanon
- A Regulatory Post Marketing Surveillance (rPMS) Study of Ryzodeg® FlexTouch® (Insulin Degludec /Insulin Aspart) to Evaluate Safety and Effectiveness in Patients With Diabetes Mellitus in Routine Clinical Practice in Korea
- A Study Investigating the Clinical Parameters Associated With the Use of Ryzodeg® (Insulin Degludec/Insulin Aspart) in a Real-world Adult Population With Type 2 Diabetes in South Korea
- RESILIENT: A Research Study, Looking at How Ryzodeg® Works in People With Type 2 Diabetes in Local Clinical Practice in Japan
- Post-marketing Surveillance (Special Use-results Surveillance) on Long-term Use With Ryzodeg®
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ryzodeg® CI brief — competitive landscape report
- Ryzodeg® updates RSS · CI watch RSS
- Novo Nordisk A/S portfolio CI